Vascular endothelial growth factor (VEGF) is a biomarker of angiogenesis, and angiogenesis is one of the characteristics of many tumors, so VEGF and VEGF receptor (VEGFR) are often used as a biomarker for tumor research and related drug studies. Creative BioMart Biomarker has a mature biomarker detection platform, which can provide customers with fast, accurate and sensitive VEGF and VEGFR detection services to help customers shorten the research cycle.
VEGF, also known as vascular permeability factor (VPF), is an important growth factor and signaling molecule that can drive tumor angiogenesis. VEGF has a highly conserved sequence and is a homodimeric glycoprotein with thermal stability. The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor (PlGF). VEGF-A promotes neovascularization and is related to vascular permeability. VEGF-C and VEGF-D are involved in the formation of new blood vessels and new lymphatic vessels in cancer tissues. VEGF functions by binding to VEGFR expressed on the surface of human vascular endothelial cells. VEGFR is a type of tyrosine kinase receptor, which is divided into three types: VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-1 and VEGFR-2 are mainly distributed on the surface of tumor vascular endothelium and regulate tumor angiogenesis. VEGFR-3 is mainly distributed on the surface of lymphatic endothelium, which is related to the formation of tumor lymphatics. Angiogenesis is important in tumorigenesis and is closely related to tumor growth and metastasis. Blocking angiogenesis is also a strategy for cancer treatment. Therefore, VEGF inhibitors have become a research direction for tumor therapeutic drugs. VEGF and VEGFR can also be used as biomarkers for drug efficacy in tumor drug research. VEGF and VEGFR have been used as tumor biomarkers in various diseases, including breast cancer, kidney cancer, liver cancer, non-small cell lung cancer, colorectal cancer, etc.
Figure 1. Actions of different VEGF isoforms on the 3 major types of VEGFRs (Alsohaimi, 2019)
Plasma and serum VEGF levels as biomarkers to predict different diseases, such as breast cancer, liver cancer, non-small cell lung cancer, colorectal cancer, etc.
Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of VEGF or VEGFR in each sample.
At Creative BioMart Biomarker, we offer VEGF detection service that includes different subtypes and receptor subtypes, you can communicate with our experts according to your research needs, and we will determine the final detection technological scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.